

A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318

Status	RECRUITING
Phase	Phase 3
Sponsor	Takeda
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (1)

- The participant has completed TAK-079-3002 (end of trial \[EOT\]) or TAK-079-1004 (EOT).

Exclusion (17)

- For TAK-079-3002 participants:
 - The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation.
- For TAK-079-1004 participants:
 - The participant has had any thrombotic or embolic event within 12 months before signing the ICF.
 - The participant has had a splenectomy within 3 months before signing the ICF.

... and 12 more (see full listing online)

Locations (98 total)

USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles, California, United States

Rocky Mountain Cancer Center, Denver, Colorado, United States

Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States

... and 95 more locations